American college of clinical pharmacy.

agents, Dr. Malesker noted variable responses with enalaprilat, a risk of extravasation with esmolol, hypotension with labetalol, rapidly developing resistance to nitroglycerin, and toxicity in patients with impaired hepatic or renal function with nitroprusside. He concluded, “In addition to the lower overall treatment cost, the higher acquisition cost of nicardipine is offset by a greater monotherapy success rate and a lower rate of complications.”